ClinicalTrials.gg
CompletedNCT02829775Updated Jan 9, 2017Results posted

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

A Phase 2/3 interventional study of Pegylated Interferon Alfa-2a and Recombinant Interferon Alfa 2a in Chronic Myelogenous Leukemia, Malignant Melanoma and Renal Cell Carcinoma, sponsored by Hoffmann-La Roche. Completed at 8 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation — 4 open to participants now, 4 under way, none of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation.

Enrollment
19th of 22
9 · median 94
Started
2004
the only one that year
Phase 2/3
2 of 26
none open now
Registered
19th of 26
by date
Lead sponsor
1 of 26
Hoffmann-La Roche

Among the 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2004, is one of 2 in phase 2/3, and was the 19th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

4 of the 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation, or all of them as a file.
02

Study summary

This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical studies NO15753 (NCT00003542) for Renal Cell Carcinoma (RCC), NO15764 (NCT number not available) and NO16006 (NCT02736721) for Chronic Myelogenous Leukemia (CML), and NO16007 (NCT number not available) for Malignant Melanoma (MM).

03

Conditions studied

  • Chronic Myelogenous Leukemia
  • Malignant Melanoma
  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have completed protocol NO15753, NO15764, NO16006 or NO16007 and responded to treatment at the end of the trial as defined in the parent protocol
  • CML participants must have a confirmed cytogenetic complete response within 2 months of entering the extension study. MM and RCC participants must have tumour assessments verifying stable or better response within 2 months of entering the extension study

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Refusal to use adequate measures among men and women of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Interferon Alfa-2A in Cancer Participants

    Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).

    Drug: Pegylated Interferon Alfa-2a · Drug: Recombinant Interferon Alfa 2a

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; Life-threatening experience (immediate risk of dying); Persistent or significant disability or incapacity; and congenital anomaly.

    Time frame: Baseline up to approximately 3 years

Secondary outcomes

  1. Number of Participants With Overall Tumor Response

    Tumor response was assessed every 6 months using hematological evaluation or any other appropriate diagnostic techniques, as per standard of care practice. The complete response (CR) and partial response (PR) status were recorded from case report form.

    Time frame: Baseline until disease progression, withdrawal or death, whichever occurred earlier (assessed every 6 months up to approximately 3 years)

07

Results

Posted Nov 17, 2016

Participant flow

A total of 9 participants were recruited in the study: 8 participants from study NO16006 (NCT02736721) and 1 participant from study NO16007 (NCT number not available).

Participant flow — Overall Study
MilestoneInterferon Alfa-2A in Cancer Participants
Started9
Completed4
Not completed5
Withdrew: Death1
Withdrew: Withdrawal by subject3
Withdrew: Disease remission1

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; Life-threatening experience (immediate risk of dying); Persistent or significant disability or incapacity; and congenital anomaly.

Time frame:
Baseline up to approximately 3 years
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs)
participantsInterferon Alfa-2A in Cancer Participants
Number of Participants With Serious Adverse Events (SAEs)1
SecondaryNumber of Participants With Overall Tumor Response

Tumor response was assessed every 6 months using hematological evaluation or any other appropriate diagnostic techniques, as per standard of care practice. The complete response (CR) and partial response (PR) status were recorded from case report form.

Time frame:
Baseline until disease progression, withdrawal or death, whichever occurred earlier (assessed every 6 months up to approximately 3 years)
Reported as:
Number · participants
Number of Participants With Overall Tumor Response
participantsInterferon Alfa-2A in Cancer Participants
CR9
PR0

Adverse events

Collected over Baseline up to approximately 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interferon Alfa-2A in Cancer Participants—1/9 (11.1%)—
Most frequent serious events
Most frequent serious events
EventInterferon Alfa-2A in Cancer Participants
Lung InfectionInfections and infestations1/9

Baseline characteristics

All participants who were recruited in the study.

Age, Continuous
Age, Continuous(years)Interferon Alfa-2A in Cancer Participants
Mean48.1 ± 18.3
Gender
Gender(Participants)Interferon Alfa-2A in Cancer Participants
Female2
Male7
08

Study locations

8 sites
  • Sofia, 1757, Bulgaria
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • Lucknow, 226 014, India
  • Moscow, 125167, Russian Federation
  • Moscow, 129110, Russian Federation
  • Kosice, 040 66, Slovakia
  • Durban, 4091, South Africa
  • Valencia, 46009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 8 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2016
First posted
Jul 12, 2016
Start
Jan 2004
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Nov 17, 2016
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02829775
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 12, 2016
Start date
Jan 2004
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Nov 17, 2016
Last update
Jan 9, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Interferon alpha-2

Start the discussion